公开(公告)号：US20230256010A1

公开(公告)日：2023-08-17

申请号：US18139553

申请日：2023-04-26

Applicant: Braintree Laboratories, Inc.

Inventor： Mark vB Cleveland ,  Edmund V. Dennett, JR. ,  Russell W. Pelham

IPC: A61K33/14 ,  A61K9/20 ,  A61K33/06 ,  A61K33/04 ,  A61P3/12

CPC classification number: A61K33/14 ,  A61K9/2013 ,  A61K9/2031 ,  A61K33/04 ,  A61K33/06 ,  A61P3/12

Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.

公开(公告)号：US20230255964A1

公开(公告)日：2023-08-17

申请号：US17639489

申请日：2020-09-18

Applicant: Bristol-Myers Squibb Company

Inventor： Sherif Ibrahim Farag Badawy ,  Jonathan R. Brown ,  Candice Y. Choi ,  Christoph Gesenberg ,  Vivienne Gary ,  John Wynne Jones ,  Umesh Kestur ,  Balvinder S. Vig ,  Xiaotian S. Yin ,  Christopher A. Zordan ,  Corey Bloom ,  Ian Yates

IPC: A61K31/501 ,  A61K9/20

CPC classification number: A61K31/501 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054

Abstract: Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyrid azine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

公开(公告)号：US20230241086A1

公开(公告)日：2023-08-03

申请号：US17984939

申请日：2022-11-10

Applicant: Celgene Corporation

Inventor： Jeffrey B. Etter ,  Mei Lai ,  Jay Thomas Backstrom

IPC: A61K31/706 ,  A61K9/20 ,  A61K9/28 ,  A61K31/7068 ,  A61K47/10

CPC classification number: A61K31/706 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2886 ,  A61K31/7068 ,  A61K9/2013 ,  A61K9/2866 ,  A61K47/10

Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

公开(公告)号：US11713311B2

公开(公告)日：2023-08-01

申请号：US17550173

申请日：2021-12-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18

CPC classification number: C07D409/12 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I):




wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11707480B2

公开(公告)日：2023-07-25

申请号：US17094541

申请日：2020-11-10

Applicant: Atea Pharmaceuticals, Inc.

Inventor： Jean-Pierre Sommadossi ,  Adel Moussa

IPC: A61K31/7076 ,  A61P31/14 ,  A61K9/08 ,  A61K9/00 ,  A61K9/20 ,  A61K31/706 ,  A61K31/7064

CPC classification number: A61K31/7076 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/706 ,  A61K31/7064 ,  A61P31/14

Abstract: The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

公开(公告)号：US11707466B2

公开(公告)日：2023-07-25

申请号：US17855242

申请日：2022-06-30

Applicant: Alkermes Pharma Ireland Limited

Inventor： Renato A. Chiarella ,  Hector Guzman ,  Paul Hurley ,  David Manser ,  Kristopher Perkin

IPC: A61K9/24 ,  A61K31/5513 ,  A61K9/20 ,  A61K31/485

CPC classification number: A61K31/5513 ,  A61K9/209 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2095 ,  A61K31/485

Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

公开(公告)号：US20230218533A1

公开(公告)日：2023-07-13

申请号：US18001411

申请日：2021-06-10

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Robert O. WILLIAMS, III ,  Mohammed MANIRUZZAMAN ,  Daniel A. DAVIS, JR. ,  Rishi THAKKAR

IPC: A61K9/20 ,  A61K41/00 ,  A61K31/4422 ,  A61K31/427 ,  B29C64/153 ,  B33Y80/00 ,  B33Y70/00

CPC classification number: A61K9/2095 ,  A61K41/00 ,  A61K31/4422 ,  A61K31/427 ,  A61K9/2027 ,  A61K9/2013 ,  A61K9/2009 ,  B29C64/153 ,  B33Y80/00 ,  B33Y70/00 ,  B29L2031/753

Abstract: The present disclosure provides pharmaceutical compositions prepared using an additive manufacturing process where the active pharmaceutical ingredient has been rendered into the amorphous form or prepared as an amorphous solid dispersion at a temperature below the melting point of the active pharmaceutical ingredient or the glass transition of the physical mixture or composition of the individual components. The present disclosure also provides methods of preparing these compositions by using properties such as the chamber and surface temperature and the electron laser density.

公开(公告)号：US20230210839A1

公开(公告)日：2023-07-06

申请号：US18091476

申请日：2022-12-30

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： William Rowe ,  Patricia Hurter ,  Christopher Young ,  Kirk Dinehart ,  Marinus Jacobus Verwijs ,  Kirk Overhoff ,  Peter D.J. Grootenhuis ,  Martyn Botfield ,  Alfredo Grossi

IPC: A61K31/47 ,  A61K9/00 ,  A61K9/28 ,  A61K9/20

CPC classification number: A61K31/47 ,  A61K9/0053 ,  A61K9/2866 ,  A61K9/2826 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/2853 ,  A61K9/2054 ,  A61K9/2018 ,  A61K9/2013 ,  A61K9/2009

Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

公开(公告)号：US20230203183A1

公开(公告)日：2023-06-29

申请号：US17987095

申请日：2022-11-15

Applicant: Eyal Levit

Inventor： Eyal Levit

IPC: C07K16/28 ,  A61K39/395 ,  A61K9/00 ,  A61K31/519 ,  A61P3/10 ,  A61K47/26 ,  A61K9/08 ,  A61K47/12 ,  A61K9/20 ,  A61K47/02 ,  A61K47/18

CPC classification number: C07K16/2887 ,  A61K39/3955 ,  A61K9/0053 ,  A61K31/519 ,  A61K9/0019 ,  A61P3/10 ,  A61K47/26 ,  A61K9/08 ,  A61K47/12 ,  A61K9/2054 ,  A61K9/2009 ,  A61K9/2027 ,  A61K47/02 ,  A61K9/2031 ,  A61K9/2013 ,  A61K9/2018 ,  A61K47/183 ,  A61K9/20 ,  A61K2039/505

Abstract: The present invention provides a method of treating insulin-dependent diabetes mellitus in a subject, comprising administering to the subject a therapeutically effective amount of a Janus kinase inhibitor, or a pharmaceutically acceptable salt or ester thereof, or a therapeutically effective amount of intravenous immunoglobulin, or a therapeutically effective amount of a therapeutic agent that destroys B lymphocytes, or a combination thereof. The present invention also provides kits containing the same.

公开(公告)号：US20230203050A1

公开(公告)日：2023-06-29

申请号：US18176653

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Aileen L. Pangan ,  Henrique D. Teixeira ,  Ayman D. Allian ,  Thomas B. Borchardt ,  Jayanthy Jayanth ,  Patrick J. Marroum ,  Fredrik Lars Nordstrom ,  Ahmad Y. Sheikh ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Peter T. Mayer ,  Ben Klünder

IPC: C07D487/14 ,  A61K47/38 ,  A61K47/12 ,  A61K31/4985 ,  A61K9/00 ,  A61K9/20

CPC classification number: C07D487/14 ,  A61K47/38 ,  A61K47/12 ,  A61K31/4985 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2027 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment(including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.